Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER vs GLYCEROL PHENYLBUTYRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Adjunctive therapy for chronic management of patients with urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase I, ornithine transcarbamylase, or argininosuccinic acid synthetase. It is indicated for all patients requiring therapy for these disorders except those with arginase deficiency.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Glycerol phenylbutyrate is metabolized by lipases to phenylbutyrate, which is then beta-oxidized to phenylacetate. Phenylacetate conjugates with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Negligible for electrolytes and dextrose (<5%).
80–90% bound to albumin (phenylacetate and phenylbutyrate)
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
0.2–0.3 L/kg (phenylbutyrate and metabolites); clinical meaning: primarily distributes in extracellular fluid
Intravenous: 100%.
Oral: ~100% (prodrug is completely hydrolyzed to phenylbutyrate); intraperitoneal: not used clinically
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce dose by 75%; GFR <15 m L/min: contraindicated.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
450-600 mg/m2/day orally in three divided doses; for children <20 kg, use 450 mg/m2/day; maximum 20 g/day.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
Start at low end of dosing range (450 mg/m2/day) and titrate based on renal function and tolerability; monitor for fluid overload.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
None.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Monitor plasma ammonia levels, neurotoxicity (somnolence, lethargy, confusion) due to elevated phenylacetate; caution in hepatic or renal impairment; contains phenylalanine; avoid use with valproic acid; may cause hyperammonemia if dosing is incorrect; fluid and electrolyte imbalance; growth retardation in pediatric patients; pancreatic enzyme replacement may be needed.
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
Known hypersensitivity to glycerol phenylbutyrate or any component; patients with arginase deficiency; patients requiring therapy for hyperammonemia who are unable to swallow capsules or have gastrointestinal obstruction.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Avoid high-protein meals without concurrent nitrogen-scavenging therapy; maintain a protein-restricted diet as prescribed. Do not mix the medication with acidic foods or drinks (e.g., orange juice, tomato juice) as it can cause precipitation.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fetal toxicity (reduced fetal weight, skeletal variations) occurred at maternally toxic doses. First trimester risk unknown; second and third trimesters: theoretical risk of maternal ammonia control affecting fetal development.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No data on excretion in human milk; M/P ratio unknown. Due to potential for adverse effects in nursing infants (ammonia elevation if mother has poor control), caution advised. Consider risk-benefit.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
No specific dose adjustment recommendations. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; dose titration based on ammonia levels is essential. Monitor ammonia weekly initially, then as needed.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
Monitor ammonia levels; glycerol phenylbutyrate is a prodrug that provides phenylbutyrate, which conjugates with glutamine to form phenylacetylglutamine, a nitrogen-scavenging agent excreted in urine. Dosing is weight-based (typically 5-12 m L/m²/day in divided doses) and must be adjusted with hepatic or renal impairment. Avoid use with probenecid as it reduces renal excretion of phenylacetylglutamine. Watch for hypernatremia and metabolic acidosis due to sodium content.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
Take with food or formula to reduce gastrointestinal side effects.,Measure dose using the provided oral syringe for accuracy.,Do not mix with acidic beverages (e.g., fruit juice) as it may precipitate.,Contact physician immediately if vomiting occurs within 20 minutes of dosing.,Maintain adequate hydration to ensure urinary excretion of waste nitrogen.,Store at room temperature, do not freeze.
No interactions on record
"Rimexolone, a corticosteroid with anti-inflammatory activity, may induce the metabolism of glycerol phenylbutyrate via hepatic enzyme induction, particularly CYP3A4. This reduces the conversion of glycerol phenylbutyrate to phenylacetate, decreasing therapeutic efficacy for hyperammonemia management. Clinically, patients may experience elevated ammonia levels, increasing the risk of neurotoxicity and hepatic encephalopathy."
"Concomitant administration of loteprednol, a corticosteroid, with glycerol phenylbutyrate, a nitrogen-binding agent used for urea cycle disorders, may reduce the therapeutic efficacy of glycerol phenylbutyrate. Corticosteroids are known to induce hepatic enzymes involved in drug metabolism, potentially accelerating the clearance of glycerol phenylbutyrate. This interaction could lead to increased ammonia levels and loss of disease control in patients with urea cycle disorders."
"Fluorometholone is a corticosteroid that can induce hepatic enzymes, particularly CYP3A4, potentially accelerating the metabolism of glycerol phenylbutyrate, a prodrug that relies on CYP3A4 for conversion to its active metabolite, phenylacetic acid. This reduction in systemic exposure to phenylacetic acid may decrease the therapeutic efficacy of glycerol phenylbutyrate in managing hyperammonemia in urea cycle disorders. Clinically, this could lead to elevated ammonia levels and breakthrough hyperammonemic episodes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER vs GLYCEROL PHENYLBUTYRATE, answered by our medical review team.
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. GLYCEROL PHENYLBUTYRATE is a Ammonia Detoxicant that works by Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER and GLYCEROL PHENYLBUTYRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. The standard adult dose of GLYCEROL PHENYLBUTYRATE is: 450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER and GLYCEROL PHENYLBUTYRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. GLYCEROL PHENYLBUTYRATE is classified as Category C. Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.